Agios Pharmaceuticals
AGIO
186 hedge funds and large institutions have $1.81B invested in Agios Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 62 increasing their positions, 57 reducing their positions, and 23 closing their positions.
74% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 23
35% more capital invested
Capital invested by funds: $1.35B → $1.81B (+$468M)
10% more funds holding
Funds holding: 169 → 186 (+17)
2.28% more ownership
Funds ownership: 108.05% → 110.34% (+2.3%)
9% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 57
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
20% less call options, than puts
Call options by funds: $12.5M | Put options by funds: $15.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$38.1M |
| 2 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$17.4M |
| 3 |
State Street
Boston,
Massachusetts
|
+$13.7M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$10.8M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
-$40.5M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$23.7M |
| 3 |
AC
Armistice Capital
New York
|
-$15M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$10.4M |
| 5 |
SCM
Suvretta Capital Management
New York
|
-$8.9M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CSS
201
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$90.6K | -4,067 | Closed |
|
|
A
202
AlphaQuest
New York
| – | -$41.5K | -1,863 | Closed |
|
|
AF
203
Advisornet Financial
Minnetonka,
Minnesota
| – | -$34.1K | -1,532 | Closed |
|
204
Group One Trading
Chicago,
Illinois
| – | -$27.7K | -1,035 | Closed |
|
|
ASN
205
Advisory Services Network
Atlanta,
Georgia
| – | -$7.79K | -350 | Closed |
|
|
GWS
206
Glassman Wealth Services
Vienna,
Virginia
| – | -$2.23K | -100 | Closed |
|
|
GI
207
Gradient Investments
Arden Hills,
Minnesota
| – | -$490 | -22 | Closed |
|
|
C
208
Covestor
London,
United Kingdom
| – | -$187 | -7 | -64% |
|
|
DPW
209
DiNuzzo Private Wealth
Beaver,
Pennsylvania
| – | -$23 | -1 | Closed |
|
AGIO Hedge Fund Activity: Q1 2024 in Review
186 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q1 2024, worth a combined $1.81B — up 35% from $1.35B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new AGIO positions and 23 closed out — a net gain of 17 holders — while 62 added to existing stakes and 57 trimmed.
The largest buyer was Farallon Capital Management, adding an estimated $38.1M. The largest seller was First Trust Advisors, exiting entirely with an estimated $40.5M sold.
- 186 institutional investors held Agios Pharmaceuticals (AGIO) as of Q1 2024, up from 169 in Q4 2023.
- Funds reported $1.81B of Agios Pharmaceuticals stock for Q1 2024, up 35% quarter-over-quarter.
- 40 funds opened new Agios Pharmaceuticals positions in Q1 2024 and 23 closed out, a net change of +17 holders.
- The largest Agios Pharmaceuticals buyer in Q1 2024 was Farallon Capital Management, an estimated $38.1M added.
- The largest Agios Pharmaceuticals seller in Q1 2024 was First Trust Advisors, an estimated $40.5M sold.
Based on aggregated 13F filings for Q1 2024.